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New Features of Systemic Vasculitides
In Allergology International (AI) Vol. 63 No. 4, we of-
fer a set of review articles entitled “New features of
systemic vasculitides”, as well as original articles and
letters to the editor. We believe that this review se-
ries will provide you a latest concept of systemic vas-
culitides.
Systemic vasculitides are pathologically character-
ized by inflammation of blood vessel walls and in-
volve various organs. After several revisions of the di-
agnostic criteria for these diseases, the Chapel Hill
Consensus Conference Nomenclature of Vasculitides
published revised nomenclature and definitions for
vasculitides (CHCC 2012) in January 2013.1 Katsu-
yama et al. summarized the previous diagnostic crite-
ria and what was new in CHCC 2012.2 In addition to
the three categories described in CHCC 1994 (large-,
medium-, and small-vessel vasculitis), four new cate-
gories were introduced : variable vessel vasculitis,
single-organ vasculitis, vasculitis associated with sys-
temic disease, and vasculitis associated with probable
etiology. Katsuyama et al. emphasize that CHCC is a
nomenclature system, not a diagnostic system that
can be used to direct clinical management. The
CHCC will be further modified in the future to reflect
new information about biomarkers and the patho-
genesis of systemic vasculitides.
Autoantibodies (autoAbs) directed against various
human antigens are found in patients with systemic
autoimmune diseases, including systemic vasculiti-
des. AutoAb production is one of the most important
immunological disorders in systemic autoimmune
diseases, and autoAb measurements also have clini-
cal significance, as described by Fujii in this issue.3 In
his review article, he focuses on three systemic
autommune diseases, including vasculitis. The auto-
Abs closely associated with these diseases are dis-
cussed from the standpoints of both their direct and
indirect pathogenic roles.
Antineutrophil cytoplasmic antibodies (ANCA) are
known to recognize neutrophil and monocyte lysoso-
mal enzymes, especially myeloperoxidase and prote-
inase.3 ANCA are thought to induce release of lytic
enzymes, causing vascular inflammation involving re-
active oxygen species and leading to systemic vasculi-
tis. Yoshida and Iino describe how otological symp-
toms such as otitis media and hearing loss have
recently been reported in patients with ANCA-
associated vasculitis (AAV).4 They postulate the need
for a new diagnostic category called otitis media with
AAV (OMAAV). Delayed diagnosis of this disorder
may lead to progression to an irreversible phase. We
thus need to be aware of OMAAV in order to reach a
correct diagnosis at an early stage and preserve pa-
tients’ hearing ability and QOL.
Ohsawa contributes a review article in commemo-
ration of his receiving the JSA Best Presentation
Award 2012.5 He summarizes the roles of histamine
H1 receptor (H1R) and H4R from the points of view
of basic research and of clinical study. H1R antago-
nists are widely used for patients with atopic dermati-
tis (AD). H4R signals play roles that are important,
but different from H1R signals, in allergic inflamma-
tion by differently expressing their receptors. Oh-
sawa et al. demonstrate that the combination of H1R
and H4R antagonists shows significant and synergis-
tic effects, similar to that of prednisolone, indicating a
novel strategy for AD using molecularly targeted
drugs.
Among the contributions to this issue, Okubo et al.
demonstrate the result of a phase III study of flutica-
sone furoate nasal spray (FFNS) for children aged
6 to 15 years with allergic rhinitis (AR).6 Although
FFNS is currently used for both adult and child AR
patients in many countries, FFNS is approved for only
adult AR patients in Asia, including Japan. In the re-
search described in this article, FFNS showed a sig-
nificant efficacy estimated by the three total nasal
symptom scores as well as turbinate swelling, nasal
discharge, and ocular symptoms without overt ad-
verse events. These results provide a basis for using
FFNS with child AR patients in Japan.
Enomoto et al. investigated the effects of adminis-
tering probiotics to pregnant mothers to prevent ec-
zema from developing in their infants after birth.7 Al-
though many clinical trials have been aimed at inves-
tigating whether probiotics help prevent atopic dis-
eases, the results are controversial. In the present ar-
ticle, a combination of Bifidobacterium strains―Bifi-
dobacterium longum BB536 and B. breve M-16V―de-
creased the risk of developing eczemaatopic derma-
titis, which supports the preventive effects of these
probiotics for newborn babies.
We offer our appreciation to all the authors for
their contributions to the present issue of Allergology
International.
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